24/7 Market News Snapshot 09 July, 2025 – Jasper Therapeutics, Inc. Common Stock (NASDAQ:JSPR)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (Nasdaq:JSPR) are discussed in this article.
Jasper Therapeutics, Inc. (Nasdaq:JSPR), a clinical-stage biotechnology firm, has recently experienced a notable surge in its stock price, rising to $3.73—an increase of 23.44%—from a previous close of $3.02, with trading volumes reaching approximately 2.33 million shares. This upward momentum has attracted significant investor interest, reflecting growing confidence in the company’s potential.

In a strategic move to refine focus and extend its financial runway, Jasper has announced a workforce reduction of about 50%. This decision aims to streamline operations and concentrate resources on the development of briquilimab, a pioneering therapeutic antibody targeting KIT (CD117) for mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The reorganization will lead to the suspension of unrelated clinical and preclinical studies, including those focused on asthma and severe combined immunodeficiency (SCID).

Ronald Martell, President and CEO of Jasper, emphasized the company’s dedication to briquilimab, noting the promising efficacy and safety observed thus far. Alongside this operational shift, Dr. Edwin Tucker will step down as Chief Medical Officer, effective August 1, 2025. Dr. Daniel Adelman, who brings a wealth of experience in clinical development from previous roles at notable biopharmaceutical companies, has been appointed as the Acting Chief Medical Officer to advance the briquilimab program.

Jasper is poised to share further insights from its ongoing BEACON and open-label extension studies later this year, endeavoring to provide innovative treatment options for patients facing challenges from mast cell-driven conditions. As the company navigates these changes, market participants are closely monitoring its progress and strategic initiatives.

Related news for (JSPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.